Covalently Cyclized FGFR Peptide for Stable Cell Proliferation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current low-molecular-weight drugs and antibody drugs are ineffective for treating certain diseases, and growth factors like bFGF are expensive and unstable, leading to high production costs for cell therapy products and cultured meat, which rely on efficient cell proliferation.
Innovation Solution
Development of a cyclic peptide with specific amino acid residues that exhibit high binding affinity and stability to the FGFR protein, used in culture media to promote cell proliferation and maintain undifferentiated potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If growth factors like bFGF are used to promote cell proliferation, then cell proliferation is improved, but production cost increases and stability decreases
Solution Approach 1:
The patent creates a cyclic peptide that copies the binding function of bFGF to FGFR without using the expensive and unstable bFGF protein itself. The cyclic peptide mimics the ligand-receptor interaction, providing the same proliferative effect at lower cost and higher stability.
Solution Approach 2:
The patent modifies the chemical structure by forming a cyclic peptide with specific amino acid sequences (including Proline at position 2 and Cysteine at position 7) that changes the stability and cost parameters while maintaining the binding affinity to FGFR, thus resolving the contradiction between productivity and reliability.
2Productivity
If growth factors like bFGF are used to promote cell proliferation, then cell proliferation is improved, but production cost increases
Solution Approach 1:
The patent creates a cyclic peptide that copies the binding function of bFGF to FGFR without using the expensive and unstable bFGF protein itself. The cyclic peptide mimics the ligand-receptor interaction, providing the same proliferative effect at lower cost and higher stability.
Solution Approach 2:
The cyclic peptide serves as a cheaper alternative to the expensive bFGF protein. While peptides can be degraded, their shorter lifetime and lower cost make them economically viable for sustained cell proliferation applications, replacing the need for expensive long-lasting growth factors.
3Reliability
If disulfide-type cyclic peptide is used to bind FGFR, then binding affinity is achieved, but stability decreases due to disulfide bond decomposition
Solution Approach 1:
The patent modifies the chemical structure by forming a cyclic peptide with specific amino acid sequences (including Proline at position 2 and Cysteine at position 7) that changes the stability and cost parameters while maintaining the binding affinity to FGFR, thus resolving the contradiction between productivity and reliability.
Solution Approach 2:
The patent creates a composite cyclic peptide structure combining specific amino acid residues (Proline, Cysteine, and other hydrophobic residues) that work together to provide both binding affinity and stability. The composite structure prevents disulfide bond decomposition while maintaining receptor binding capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyclic peptide provides excellent binding affinity and stability to FGFR, reducing costs and improving the efficiency of cell proliferation, thereby lowering the production costs of cell therapy products and cultured meat.
Implementation Method 1
a cyclic peptide having an amino acid sequence represented by X1-X2-X3-X4, in which the cyclic peptide contains a cyclized portion that is cyclized via covalent bonding
Implementation Method 2
the cyclic peptide contains a cyclized portion that is cyclized via covalent bonding
Data Source
AI summary
An object of the present invention is to provide a cyclic peptide or a salt thereof and a cyclic peptide complex or a salt thereof, which have excellent binding affinity to an FGFR protein and excellent stability, and to provide a culture medium composition, a material for purification, a material for labeling, a material for cell regulation, and a material for accumulation, which use the cyclic peptide or a salt thereof and the cyclic peptide complex or a salt thereof.A cyclic peptide or a salt thereof, the cyclic peptide being a peptide having an amino acid sequence represented by X1-X2-X3-X4, in which the cyclic peptide contains a cyclized portion that is cyclized via covalent bonding, and the cyclized portion includes a structure represented by Formula (2),X1 represents an alanine residue, a leucine residue, an isoleucine residue, a valine residue, a phenylalanine residue, a tyrosine residue, or a threonine residue, X2 represents an amino acid residue having an aromatic residue on a side chain, X3 represents any amino acid residue, and X4 represents an alanine residue, a glycine residue, a phenylalanine residue, a tyrosine residue, a tryptophan residue, a serine residue, or a histidine residue, in Formula (2), Z1 and Z2 each independently represent a linking group, and m represents an integer of 1 to 10.